some years to diagnose thrombotic disorders, only recently has it been possible to measure specifically the products of fibrin breakdown in the presence of fibrinogen degradation products, by using monoclonal antibodies. We have evaluated a preparation of latex particles coupled to the monoclonal antibody DD-3B6/22, which is specific for cross-linked fibrin degradation products (XDP) and allows accurate discrimination between normal and pathological conditions. Of samples from 515 apparently healthy volunteers, 97.7% failed to agglutinate the latex; the normal reference interval for XDP determined by enzyme immunoassay was <78-320 p.g/L. The use of different anticoagulants with or without the addition of a protease inhibitor had no significant effects on the results of the latex assay. The latex preparation provides a useful, rapid diagnostic tool for assaying small numbers of samples or as an emergency test.
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Fibrin clots are formed as a response to tissue damage, by polymerization ofsolublefibrin to a network offibrin fibers (1) immunoassay (9)and,more recently, by theuse ofpolystyrene latex particles to which an antiserumhas been attached (10, 11) .
Based on the use of polyclonal antibodies, these assays, although rapid and widely used, were not specific for fibrin breakdown products but also measured fibrinogen derivatives. The use of the monoclonal antibody DD-3B6/22 to D dimer introduced the specificity required to differentiate between fibrin and fibrinogen breakdown products.
Initial studies (12, 13) to show the feasibility of this monoclonal antibody method for determination of XDP indicated that it was an improvement over the older FDP tests, being more specific for the presence of clots. This is particularly important during therapy with fibrinolytic agents, which break down both fibrin and fibrinogen.
For routine clinical application a robust, stable, and reproducible reagent is essential. To this end, a new covalently coupled latex has been produced. We report here the evaluation of this latex preparation and of its application to the diagnosis of thrombotic disorders.
Patients and Methods

Patients and Volunteers
Blood was taken from three groups of subjects for the following three studies. The data were analyzed separately.
Effect of sample preparation. To study whether serum or plasma was the more appropriate sample for the latex assay, we used blood from nine patients with coagulation-associated conditions and from 11 ostensibly healthy volunteers. #{149} The effect of adding aprotinin to plasma or serum.
#{149}
The stability of samples when stored at room temperature for 0 and 24 h; at 4 #{176}C for three, seven, 10, and 14 days; and at -20 #{176}C for one and 17 days.
There was insufficient blood from some subjects for analysis of all of these combinations.
Before statistical analysis, we transformed the latex assay results to a numerical scale closely approximating the log2 value of the lowest dilution that gave a positive latex result, Normal reference interval. The upper one-tailed 95% confidence limit for EIA was used to define the reference interval and was estimated directly from the 95th percentile in the distribution of 515 readings from ostensibly normal subjects. For the latex assay, a negative agglutination was normal; we assessed the reliability of this observation by considering the proportion of normals who responded in this way.
Thrombotic patients. Graphical comparisons with normal reference intervals were used to illustrate the distinction between results from patients and those from normal volunteers and to show the close association between the ELA and latex assay systems.
Results
Comparison of sample preparations. There were no statistical differences between concentrations of XDP in plasma prepared with heparin, EDTA, or citrate as anticoagulants. Serum without thrombin gave higher results, probably because of incomplete clotting (Figure la Figure 3 . Because 97.7% of the normal results were latex negative, a negative result is an acceptable normal reference value, having substantially more than the usual95% confidence limits. In the EIA, 169 volunteershad circulating concentrations of XDP below the detection limit(78 .zgfL); fewer than 5% of the volunteers had XDP concentrations >320 g/L. The normal reference interval is thus <78-320 ,ug/L (95% confidence limit).
Thrombotic patients. All patients presenting with thrombotic disorders had measurable concentrations of XDP, 94% of which considerably exceeded the normal reference interval by EIA (Figure 4 ). Only one of these patients, who had been treated with heparin, had a negative result for the latex agglutination test.
Correlation between methods.
A highly significant positive association between XDP measured by latex and by EIA was indicated by the use of Kruskal-Goodman gamma statistics for the normal group and Spearman's rank correlations for the group of patients (Spearman's rank correlation of patients' data = 0.82; P <0.0001). The relationship between the logarithms of the ELA results and the transformed latex results is essentially linear (Figure 5) , with the bulk of normal being at one extreme and the patients' result can be obtained by serial dilution of samples. In contrast to the FDP latex assays, plasma can be used, which allows very rapid processing, there being no need to wait for the sample to clot for senun formation.
Most tests for FDP require special tubes containing thrombin and trypsin inhibitor. The latex assay can be performed on routine samples taken for hematological examination and need no special treatment. The discrimination between normal subjects and thrombotic patients islesspronouncedwith serum unless tubes containing thrombin are used.Samples are stable in storage and can be kept at 4 #{176}C for as long as two weeks, allowing batching of samples, where required.
Samples were also suitable for assay after 24 h at room temperature and after frozen storage. There was no advantage conferred by the addition of aprotinin to the plasma or serum samples, and there were no statistical differences between any of the anticoagulants at any of the times, tested with or without aprotinin. Increased XDP concentrations were seen in 47 of 50 patients with coagulation-associated disorders by EIA; 49 showed positive latex agglutination (Figure5).The patient with the negative latex test, whose concentration of D dimer by EJA was 612 pg/L, had been treated with hepann. Because purified D dimer cross-reacts less in the latex test than in the two-site EIA (12), the overlapping results seen in these studies may reflect the size distribution of the crosslinked polymers circulating in patients with coagulation disorders. If so, using both of these techniques to measure XDP would provide additional information about patients with thrombotic diseases.
